Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy

REFERENCES

• Gonzalez-Scarano F, Martin-Garcia J. The neuropathogen-esis of AIDS. Nat Rev lmmunol. 2005;5:69–81.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J lmmunol. 1999;163:2953–2959.
   PubMed Web of Science ®Google Scholar
• Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central ner-vous system. Cell Death Differ 2005;12\(suppl 1):878–892.
   PubMed Web of Science ®Google Scholar
• Maurer M, von Stebut E. Macrophage inflammatory pro-tein-1. Int J Biochem Cell Biol. 2004;36:1882–1886.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Watson V, Else L, Gisslen M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS. 2009;23:2537–2540.
   PubMed Web of Science ®Google Scholar
• Croteau D, Best BM, Letendre S, et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CCR5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012;26(7):890–893.
   PubMed Web of Science ®Google Scholar
• Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptorutilizationinpairedcerebrospinalfluidandplasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191:890–898.
   PubMed Web of Science ®Google Scholar
• Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem. 2012;120:106–114.
   PubMed Web of Science ®Google Scholar
• Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Mar-kovitz DM. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology. 2003;307:122–134.
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Mengozzi M, et al. Elevated cerebro-spinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 1998;12:1327–1332.
   PubMed Web of Science ®Google Scholar
• Garvey L, Nelson M, Latch N, Erlwein OW, et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacoki-netic and cerebral metabolite study [published online ahead of print October 10,2011]. J Antimicrob Chemother
   Google Scholar
• Winston A, Garvey L, Scotney E, et al. Does acute hepa-titis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat. 2010;17:419–426.
   Google Scholar
• Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treat-ment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50:920–929.
   PubMed Web of Science ®Google Scholar
• Marcus CD, Taylor-Robinson SD, Sargentoni J, et al. 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metabol Brain Dis. 1998;13:123–136.
   PubMed Web of Science ®Google Scholar
• Kanowski M, Kaufmann J, Braun J, Bernarding J, Tem-pelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med. 2004;51:904–912.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim IJ, Kim YK, et al. Probabilistic anatomic mapping of cerebral blood flow distribution of the middle cerebral artery. J Nud Med. 2008;49:39–43.
   Web of Science ®Google Scholar
• Yilmaz A, Verhofstede C, D'Avolio A, et al. Treat-ment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;55:590–596.
   PubMed Web of Science ®Google Scholar
• Dahl V, Lee E, Peterson J, et al. Raltegravir treatment inten-sification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011204:1936–1945.
   Google Scholar
• Luster AD, Leder P. IP-1O, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 1993;178:1057–1065.
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Früs-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641.
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spec-trum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721–4732.
   PubMed Web of Science ®Google Scholar
• Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fon-tana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol. 1999;93:172–181.
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Yarchoan R, et al. Higher macro-phage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptom-atic HIV-1 infection. Proc Nati Acad Sci USA. 2000;97: 13812–13817.
   PubMed Web of Science ®Google Scholar
• Garcia-Zepeda EA, Combadiere C, Rothenberg ME, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosino-phils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 1996;157: 5613–5626.
   PubMed Web of Science ®Google Scholar
• Gamo K, Kiryu-Seo S, Konishi H, et al. G-protein-coupled receptor screen reveals a role for chemokine receptor CCR5 in suppressing microglial neurotoxicity. J Neurosci. 2008;28:11980–11988.
   PubMed Web of Science ®Google Scholar
• Gilliam BL, Riedel DJ, Redfield RR. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med. 20119 (suppl 1):59.
   Google Scholar
• Lee PL, Yiannoutsos CT, Ernst T, et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging. 2003;17: 625–633.
   PubMed Web of Science ®Google Scholar
• Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819–1825.
   PubMed Web of Science ®Google Scholar
• Garvey L, Pavese N, Politis M, Ramlackhansingh A, Taylor-Robinson S, Brooks D, Winston A. Microglial cell activa-tion is visualized with [11C]-PK11195 positron emission tomography in neurologically asymptomatic HIV-infected subjects on effective ART [abstract 78LB]. Presented at: Conference on Retroviruses and Opportunistic Infections; March 5–8, 2012; Seattle, Washington.
   Google Scholar
• Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003;85:1299–1311.
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307: 1434–1440.
   PubMed Web of Science ®Google Scholar